NCT00862693

Calcitriol in the Treatment of Immunoglobulin A Nephropathy

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Peking University First Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Immunoglobulin A (IgA) nephropathy is the common primary glomerulonephritis in the world. Much literature suggests that vitamin D and its analogs have profound effects on immune system function and glomerular mesangial cell proliferation. Therefore, the investigators plan to conduct a randomized clinical study to evaluate the efficacy of Calcitriol in the treatment of IgA nephropathy. Forty patients with biopsy-proven IgA nephropathy will be recruited. They will be randomized to Calcitriol for six months or no treatment. Proteinuria, renal function, serum and urinary inflammatory markers will be monitored. This study will explore the potential anti-proteinuric and anti-inflammatory effects of Calcitriol in the treatment of IgA nephropathy, which has no specific treatment at present.

Conditions

• Glomerulonephritis
• Autoimmune Diseases

Interventions

Type	Name	Description
DRUG	Calcitriol	0.5ug/Biw

Timeline

• Start date: 2009-03-01
• Primary completion: 2010-08-01
• Completion: 2011-03-01
• First posted: 2009-03-17
• Last updated: 2011-02-17

Locations

1 site across 1 country: China